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BACKGROUND: Maternal cytomegalovirus (CMV) and rubella infections have adverse neonatal 
outcomes. Both CMV and rubella are more widespread in developing countries and in communities with 
lower socioeconomic status. The aim of this study was to investigate sero-prevalence of CMV and rubella 
infection and associated possible risk factors.  
METHOD: Using cross sectional study design a total of 200 pregnant women were consecutively 
recruited starting from June and July 2014. Blood samples were collected, and structured questions were 
used to gather socio-demographic and risk factor related data. ELISA was used to detect CMV (IgG, 
IgM) and rubella IgM. SPSS version 20 was used to analyze the data, and regression was also performed. 
RESULTS: Out of 200 pregnant women, 88.5%, 30(15.5%) and 4(2.0%) were CMV-IgG, CMV- IgM, 
and rubella-IgM positive, respectively. Women who were immune/positive only for IgG were 73.5%. The 
second group was those with primary infection [IgG (+) plus IgM (+)] and this consisted of 15.0% 
participants. Eleven percent of the participants were at high risk for primary infection during their 
pregnancy. One pregnant woman was identified as having a recent primary infection. In this study, no 
statistically significant association was detected between CMV infection with idependent factors (p-
value>0.05). 
CONCLUSION: In addition to detection of high prevalence of CMV, detecting recent infection of rubella 
worsens the outcome of the disease. Rubella vaccine should be taken into consideration after large scale 
surveillance. However, screening of all pregnant women for CMV infection may not be cost-effective as 
in the countries with high seropositivity.  
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Human cytomegalovirus (CMV) is a member of 
the family Herpesviridae and belongs to the 
subfamily betaherpesviridae. CMV has worldwide 
distribution, infects humans of all ages and all 
socioeconomic groups, and with no seasonal or 
epidemic patterns of transmission (1). It is the 
most common cause of congenital infection with 
birth prevalence of about 0.5% (range 0.2-2.5 
percent), and a common cause of deafness and 
intellectual impairment worldwide (2,3,4).  
In utero transmission of CMV can occur following 
primary maternal infection during pregnancy but 
can also occur in women with natural immunity, 
either because of the reactivation of latent virus or 
by re-infected with a different strain (5). 
Postnatally, CMV is also transmitted from mother 
to child through breastfeeding and close contact 
(6). The transmission risk is the proportion of 
mothers undergoing a primary infection in a given 
trimester and/or the preconception period who
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transmitted CMV to the fetus (7). While CMV has 
asymptomatic infection, rubella infection is mild 
or self limiting disease, transmitted through 
respiratory system and to growing fetus through 
placenta (8).  
Maternal infection especially during the first 
trimester is associated with adverse neonatal 
outcome which encompass heart disease, cataract 
and deafness collectively known as congenital 
rubella syndrome which had a major neonatal 
morbidity and burden to families (9). Although 
incidence of rubella infection is reduced 
worldwide, some African countries like 
Mozambique still have a high incidence (95.3%) 
(10,11). Rubella vaccine is cost-effective and cost-
beneficial. Therefore, since the year 2000 WHO 
proposed an introduction of rubella vaccine 
program in each country (12). Studies conducted 
in other parts of the world have mentioned about 
risk factors, primarily in women of childbearing 
age. However, no data exists regarding risk factors 
associated with CMV acquisition in the setting 
among pregnant women. Pregnant women engage 
in personal behaviors (such as saliva sharing 
behaviors, including sharing drinks, kissing and 
sexual activity) and have exposures (such as care 
of infants and toddlers, gestations, abortions, 
parity, and group living situations), all of which 
may place pregnant women at risk. Given the 
likelihood of an effective vaccine in the near 
future (13), it is critical to understand the 
prevalence and risk factors for CMV infection 
among pregnant women.  
The basic data concerning CMV and rubella 
infections during pregnancy is important for health 
planners and care providers. Therefore, the 
objective of this study was to determine the 
seroprevalence, associated risk factors of CMV 
and rubella infection among pregnant women.  
MATERIALS AND METHODS 
 
A cross sectional study was conducted in St. 
Paul’s Hospital Millennium Medical College 
(SPHMMC), Addis Ababa, Ethiopia. It is an urban 
setting and tertiary hospital for Ethiopian and 
teaching hospital for national and international 
students. The hospital provides out- and in-patient 
services with 370 beds. Accordingly, patients 
being seen at SPHMMC come from all over the 
Northern, Western, Southern and Eastern parts of 
Ethiopia. The sample size for the study was 
calculated using the formula (n = (zα/2)2 p (1-p)/ 
d2) for estimating a single population proportion 
at 95% confidence interval (CI) (Zα/2 = 1.96), 5% 
margin of error, and 10% non-respondents rate 
based on IgM seroprevalence of CMV from a 
study in Sudanees pregnant women 6.0 % (14). 
Therefore, the minimum sample size for 
seroprevalence of CMV survey was 97. However, 
a total of 200 study participants were 
consecutively selected to maximize the findings 
and to get a conclusive information about 
seroepidemiology of cytomegalovirus among 
pregnant women in the study settings.   
All pregnant women between 17-37 years of 
age, and who were volunteer to give consent to 
participate in the study were eligible to be 
included. Pregnant women aged less than 
seventeen were excluded from the study. 
Data collection: Venous blood samples were 
collected from 200 pregnant women attending 
antenatal clinic between June 1 and July 30, 2014. 
Samples were collected under aseptic conditions 
and transported using ice-box to Ethiopian Public 
Health Institute (EPHI), and the experiment was 
performed in EPHI. 
A total of 26 items of standard structured 
questions were designed to collect information 
regarding socio-demographics and risk related 
data; such as history of abortion, frequency of 
abortion, number of children in the household, 
number of disabled children, long time fever, 
presence of mentally retarded child in the 
household, gestational age and parity. The 
questionnaire was first developed in English and 
translated into Amharic (the local language), and 
then pre-tested (to improve the quality and clarity 
of errors during translation) in non-selected health 
institutions among fifty mothers to assess the 
content validity, appropriateness and question 
comprehensibility. The questionnaire was revised 
accordingly. Three data collectors from the 
institution in the study area were selected. 
Training was given for the data collectors for two 
day on how to conduct the interview, content of 
the questionnaire, data quality, and ways to 
approach respondents. The first author checked 
items of the questionnaire every day for 
completeness. Incomplete items were excluded. 
Five percent of the interviewed participants were  
 




randomly selected and re-interviewed by the first 
author. 
Laboratory method: CMV-specific 
immunoglobulin (Ig) IgG and IgM were analyzed 
by using the ELISA test kits (Diagnostic 
Automation, Inc., USA) according to 
manufacturer’s guideline. Briefly, purified CMV 
antigen is coated on the surface of micro wells. 
Patient serum was then added to wells. If the 
antigen is present, then it will bind to the CMV 
IgM/IgG specific antibody. All unbound materials 
are washed away and an enzyme conjugate is 
added to the well. The conjugate, then binds to the 
antibody-antigen complex. Excess enzyme 
conjugate is washed off and TMB Chromogenic 
Substrate is added. Intensity of the color generated 
by the bound conjugate is proportional to the 
amount of IgG/IgM specific antibody present in 
the sample. Results are then read by a micro-well 
reader compared in a parallel manner with 
calibrator and controls. Quantitative analysis for 
CMV (IgG and IgM) and rubella (IgM) were 
performed, and the assay result interpreted as 
IU/mL. The manufacturer’s instructions were 
followed for the cutoff points, which was < 1.1 
IU/mL for CMV IgG and IgM. Results < 1.0 OD 
value was considered negative for rubella IgM. 
Data Analysis: The data were entered (with 
double entry) and cleaned with Epidata version 
3.1, and analyzed by using SPSS version 20. 
Statistical significance was considered when P-
value <0.05. CMV-IgG, IgM and Rubella IgM 
prevalence was determined by dividing the 
number of infected individuals to the total number 
of individuals screened for CMV and Rubella 
infection. Frequency distribution tables were used 
to quantify participants’ age range, gestation, 
occupation, parity and risk factors of CMV 
positivity rate. Chi-square and Fisher’s exact test 
was used to see the association of risk factors to 
CMV prevalence rate. Multivariate and univariate 
logistic regression analysis was used to quantify 
the effect of different clinical and obstetrical risk 
factors on CMV seroprevalence. Ninty-five 
percent confidence intervals were calculated for 
odds ratio. Values were considered statistically 
significant when P-value < 0.05.  
Individuals who were positive for Rubella 
infection were low in number. Therefore, a 
regression was not applicable to see statistically 
significant association between the dependent and 
independent factor.  
Ethical approval: Ethical approval for this study 
was obtained from the Institutional Review Board 
(IRB) of St.Paul’s Hospital Millennium Medical 
College Research Ethics Committee (ref: 
2014/P.M23/119) with 16/05/2014 date of 
approval. Women gave written informed consent 
before taking part in the study. All infected 
mothers received a serious follow-up by 




Socio-demographic and obstetrical 
characteristics: A total of 200 pregnant women 
were enrolled in the study. The mean (SD) of 
maternal age, parity and gestational age were 26.7  
Table 1: Socio-demographic variables of 200 pregnant 
women at St.Paul’s Hospital Millennium Medical 
College, Addis Ababa, Ethiopia, 2014. 
Variable Frequency Percent 
Maternal Age   
<19 7 3.5 
20-25 87 43.5 
26-31 73 36.5 
32-37 33 16.5 
Educational status   
Illiterate  38 19.0 
Primary 57 28.5 
Secondary 64 32.0 
Certificate 26 13.0 
Diploma 9 4.5 
Degree 6 3.0 
Marital status   
Married 197 98.5 
Other 3 1.5 
Occupation   
Civil servant 14 7.0 
Businesswoman 18 9.0 
Housewife 133 66.5 
Student 5 2.5 
Others 30 15.0 
Gestational Age   
1
st
 Trimester 17 8.5 
2
nd
 Trimester 44 22.0 
3
rd
 Trimester 139 69.5 
Parity   
0 65 32.5 
1 15 7.5 
2 58 29.0 
3 40 20.0 
>4 22 11.0 
Note: Gestational age was in week then converted to 
the categories. 





(4.7) years, 1.75 (1.5), 7.3(2.2) months, 
respectively. Almost all, 197(98.5%), of the 
participants were married, and 64(32. %) 
completed a secondary education. More than half 
(66.5%) of the participants were housewives; 14 
(7.0%) were government employees and the least 
5(2.5%) were students. Regarding gestational age 
distribution, nearly two third of the mothers, 
139(69.5%), were in third trimester pregnancy and 
followed by 22.0% second trimester pregnancy 
(Table 1).  
The mean CMV positivity age was 26.1 with 
standard deviations’ of 4.9. The frequency of 
CMV infection was highest among pregnant 
women in the 3
rd
 trimester (69.5%), those with 
second and first trimester pregnancy 21.5 and 
9.0% respectively. More than 68% of the 
housewives were positive for the virus (Table 2).
 
Table 2: Distributions of CMV with Obstetrical, socio-demographical and clinical characteristic of the 
pregnant women in St.Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia 2014. 
 
 










Age in Year 26.7(4.7) 25.67(4.6)  26.1(4.9)  
Age group      
  ≤20 17(8.5) 4(12.9) 0.8 15(8.5) 0.3 
  20-25 77(38.5) 12(38.7)  64(36.2)  
  26-31 73(36.5) 11(35.5)  68(38.4)  
  32-37 33(16.5) 4(12.9)  30(16.9)  
Educational Status      
  Illiterate 38(19.0) 4(12.9) 0.5 31(17.5) 0.1 
  Primary  57(28.5) 12(38.7)  53(29.9)  
  Secondary 64(32.0) 11(35.5)  60(34.0)  
  Certificate 26(13.0) 2(6.4)  21(11.9)  
  Higher education 15(7.5) 2(6.4)  12(6.8)  
Occupation      
  Civil servant  14(7.0) 1(3.2) 0.7 12(6.8) 0.3 
  Housewife 133(66.5) 21(67.7)  121(68.4)  
  Business woman,Student & others 53(26.5) 9(29.0)  44(24.8)  
Gestational age in month      
  1
st
 Trimester 17(8.5) 1(3.2) 0.5 16(9.0) 0.7 
  2
nd
 Trimester 44(22.0) 8(25.8)  38(21.5)  
  3
rd
 Trimester 139(69.5) 22(71.0)  123(69.5)  
Number of parity      
  0 65(32.5) 11(35.5) 0.4 56(31.6) 0.3 
  1 15(7.5) 1(3.2)  14(7.9)  
  2 58(29.0) 9(29.0)  55(31.1)  
  3 40(20.0) 4(12.9)  33(18.6)  
  ≥4 22(11.0) 6(19.4)  19(10.7)  
No. children in house      
  0 67(33.5) 10(32.2) 0.8 57(32.2) 0.4 
  1 50(35.0) 7(22.6)  47(26.5)  
  2 49(24.5) 7(22.6)  44(24.9)  
  +3 34(17.0) 7(22.6)  29(16.4)  
 
 
        Sero-prevalence of Cytomegalovirus…                                             Mamuye  Y.G  et al 
            
 
431 
Table 2 continued… 
 
Seven month of child (F-test)      
  No 193(96.5) 29(93.5)  171(96.6)  
  Yes 7(3.5) 2(6.5) 0.29 6(3.4) 0.58 
History of abortion (F-test)      
  No 152(76.0) 24(77.4)  132(74.6)  
  Yes 48(24.0) 7(22.5) 1.00 45(25.4) 0.298 
Frequency of abortion (F-test)      
  0 152(76.0) 24(77.4)  132(74.6)  
  1 34(17.0) 4(12.9)  33(18.6)  
  ≥2 14(7.0) 3(9.7)  12(6.8)  
Child death (F-test)      
  No 186(93.0) 30(96.8)  175(98.9)  
  Yes 24(7.0) 1(3.2) 0.45 2(1.1) 0.70 
Mental retarded child (F-test)      
  Yes 198(99.0) 28(90.3) 0.28 165(93.2) 1.00 
  No 2(1.0) 3(9.7)  12(6.8)  
Long term fever (F-test)      
  No 194(97.0) 29(93.5) 0.23 173(97.7) 0.14 
  Yes 6(3.0) 2(6.5)  4(2.3)  
Note: Data are as number and percentage, Chi-square, Fisher’s Test. Gestational age was in week then converted to the 
categories, marital status was expressed in four categories (Married, Divorced, Separated, Widowed), Occupation were 
categorized based on their life style status. Abortion was recorded if there is any either of spontaneous abortion or 
medical termination. Long term fever = a fever last longer than three or four days after noticed by a pregnant women. 
Number of children = toddlers.  
 
 
Seroprevalence: Out of the total 200 pregnant 
women, 177(88.5%; 95% CI: 84.0-94.0) were 
positive for anti-CMV-IgG antibodies and 
31(15.5%; 95% CI: 10.5-21.0) were positive for 
CMV-IgM. Twenty-two (11.0%) individuals were 
sero-negative for CMV. All except one CMV-IgM 
positive pregnant women were positive for CMV-
IgG. These were categorized into four types of re-
sponses. The first category was with previous 
exposure CMV [IgG (+) plus IgM (-)]. This 
constituted 73.5% of the women. The second 
group was those with active (primary/latent) 
infection [IgG (+) plus IgM (+)] and this consisted 
of 15.0% respondents. The third group also had 
twenty-two women who were susceptible to 
primary CMV infection [IgG (-) plus IgM (-)]. 
The last category of women was those with [IgG 
(-) plus IgM (+)], and therefore, one individual 
was included in this category, and had a recent 











Table 3: Seroprevalence of CMV-specific IgG and IgM, and Rubella IgM antibodies among pregnant 
women (n=200) in St.Paul’s Hospital millennium Medical College, Addis Ababa, Ethiopia 2014. 
 
Immune responses Number       Percent Interpretation 
IgG(+) IgM (-) 147                  73.5  
Previous Exposure 
IgG(+) IgM (+) 30                     15.0  
Active (Primary/Latent) infection 
IgG(-) IgM (-) 22                    11.0 Susceptible to primary CMV infection 
IgG(-) IgM (+) 1                       0.5 Recent primary infection 
IgM(+) 4 Primary Rubella infection 
 
Risk Factors: Among the participants, 8.5% were 
between age groups of ≤20, 38.5% were between 
21-25, 36.5% were between 26-31 and 16.5% 
were above 32. The prevalence of infection among 
age groups ≤20, 21-25, 26-31 and ≥32 was 88.2% 
(CI: 0.1-3.2), 83.1% (CI: 0.3-10.3), 93.1% (CI: 
0.2-8.8), and 90.1% respectively. However, 
multivariate logistic regression analysis showed 
that no stastically significant variables were found. 
There was no significant association detected 
between sero-positivity rate of cytomegalovirus 
and educational status, occupation, gestational age 
and parity.  
 None of the pregnant women had history of 
jaundice; whereas 24.0% had history of abortion, 
of whom 17.0% had at least one frequency of 
abortion. Among those who had history of 
abortion, 93.7% (CI: 0.6-38.6) were sero-positive. 
From the participants, 7.0% had a history of dead 
child. Among mothers who had history of child 
lose, 85.7% (CI: 0.3-6.3) were positive for the 
infection. Pregnant women who had no toddler in 
the house hold were 33.5%. Among the mothers 
who had no children in the household, 85.1% were 
seropositive. However, there was no single 
independent factor for the infection of 
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Table 4: Association of CMV with Obstetrical, socio-demographical and clinical characteristic of the pregnant women in SPHMMC, Addis Ababa, Ethiopia 2014    
                                                          
CMV-IgM+     CMV-IgG+   
Characteristics Negative(N=169) Positive(N=31) AOR 95%CI P-value Negative(N=23) Positive(N=177) AOR 95% CI P-value 
Maternal Age           
≤20 13 (76.5) 4(23.5) 1   2(11.8) 15(88.2) 1   
20-25 65 (84.4) 12(15.6) 0.6 0.2-2.2 0.43 13(16.9) 64(83.1) 0.7 0.1-3.2 0.6 
26-31 62 (84.9) 11(15.1) 0.6 0.2-2.1 0.40 5(6.9) 68(93.1) 1.8 0.3-10.3 0.5 
32-37 29 (87.9) 4(12.1) 0.4 0.1-2.1 0.30 3(9.9) 30(90.1) 1.3 0.2-8.8 0.8 
Marital Status           
Married 166 (84.3) 31(15.7) NA NA NA 22(11.2) 175(88.8) 3.9 0.3-45.7 0.3 
Others 3 (100.0) 0(0.0)    1(33.3) 2(66.7) 1   
Educational Status           
Illiterate 34 (89.5) 4(10.5) 0.7 0.1-4.7 0.7 7(18.4) 31(81.6) 1.1 0.2-5.0 0.9 
Primary 45 (78.9) 12(21.1) 1.7 0.3-8.7 0.5 4(7.0) 53(93.0) 3.3 0.6-16.8 0.1 
Secondary 53 (82.3) 11(17.7) 1.3 0.3-6.8 0.7 4(6.3) 60(93.7) 3.7 0.7-18.9 0.1 
Certificate 24 (92.3) 2((7.7) 0.5 0.1-4.3 0.5 4(16.0) 21(84.0) 1.1 0.2-5.2 0.9 
Higher education 13 (86.7) 2(13.3) 1   3(20.0) 12(80.0) 1   
Occupation           
Civil Servant 13 (92.9) 1(7.1) 1   2(4.3) 12((85.7) 1   
Housewife 112 (84.2) 21((15.8) 2.4 0.3-19.6 0.4 12(9.0) 121(91.0) 1.7 0.3-8.4 0.5 
Businesswoman, student 
& Others 
44 (83.0) 9(17.0) 2.7 0.3-22.9 0.4 9(17.0) 44(83.0) 0.8 0.2-3.4 0.8 
Gestational Age           
1
st
 trimester 16 (94.1) 1(5.9) 1   1(5.9) 16(94.1) 1   
2
nd
 Trimester 36 (81.8) 8(18.2) 0.3 0.0-2.6 0.3 6(13.6) 38(86.4) 2.1 0.3-16.8 0.5 
3
rd
 Trimester 117 (84.2) 22(15.8) 1.2 0.5-2.9 0.7 16(11.5) 123(88.5) 0.8 0.3-2.2 0.7 
Parity           
0 54 (83.1) 11(16.9) 1   9(3.8) 56(86.2) 1   
1 14 (93.3) 1(6.7) 0.3 0.0-2.95 0.3 1(6.7) 14(93.3) 2.3 0.3-19.2 0.5 
2 49 (84.5) 9(15.5) 0.9 0.3-2.4 0.8 3(5.2) 55(94.8) 2.9 0.7-11.5 0.1 
3 36 (90.0) 4(10.0) 0.5 0.2-1.8 0.3 7(17.5) 33(82.5) 0.8 0.3-2.2 0.6 
>4 16 (72.7) 6(27.3) 1.8 0.6-5.8 0.3 3(3.6) 19(86.4) 1.0 0.2-4.2 0.9 
No. children in house 
hold 
          
0 57 (85.1) 10(14.9) 1   10(4.9) 57(85.1) 1   





1 43 (86.0) 7(14.0) 0.9 0.3-2.6 0.9 3(6.0) 47(94.0) 2.7 0.7-10.6 0.1 
2 42 (85.7) 7(14.3) 0.9 0.3-2.7 0.9 5(10.2) 44(89.8) 1.5 0.5-4.8 0.5 
>3 27 (79.4) 7(20.6) 1.5 0.5-4.3 0.5 5(4.7) 29(85.3) 1.0 0.3-3.2 1.0 
Child death occurrence           
No 158 (84.9) 28(15.1) 1   21(11.3) 165(88.7) 1   
Yes 11 (78.6) 3(21.4) 1.5 0.4-5.9 0.6 2(14.3) 12(85.7) 1.3 0.3-6.3 0.7 
Seven month child        1   
No 164 (85.0) 29(15.0) 1   22(11.4) 171(88.6) 1   
Yes 5 (71.4) 2(28.6) 2.3 0.4-12.2 0.3 1(14.3) 6(85.7) 1.3 0.1-11.3 0.8 
Abortion           
No 128 (84.2) 24(15.8) 1   20(13.2) 132(86.8) 1   
Yes  41 (85.4) 7(14.6) 0.9 0.4-2.3 0.8 3(6.3) 45(93.7) 2.3 0.6-8.0 0.2 
Frequency of Abortion           
0 128 (84.2) 24(15.8) 1   20(13.2) 132(86.8) 1   
1 30 (88.2) 4(11.8) 0.7 0.2-2.2 0.5 1(2.9) 33(97.1) 5.0 0.6-38.6 0.1 
>2 11 (78.6) 3(21.4) 1.5 0.4-5.6 0.6 2(14.3) 12(85.7) 1.0 0.2-4.4 0.9 
Mental retarded child           
No  168 (84.8) 30(15.2) 1   23(11.6) 175(88.4) NA  NA 
Yes 1 (50.0) 1(50.0) 5.6 0.34-
92.0 
0.2 0 2(100.0)    
Long time fever           
No 165 (85.1) 29(14.9) 1   21(10.8) 173(89.2) 1   
Yes 4 (66.7) 2(33.3) 2.8 0.5-16.3 0.2 2(33.3) 4(66.7) 4.1 0.7-23.8 0.1 
Data are expressed in Number, Percent, OR= Odds Ratio, CI= Confidence Interval 
Adjusted OR (adjusted odds ratio from multivariable logistic regression model) = when the effect of risk factors on CMV seroprevalence is evaluated the analysis 
















        Sero-prevalence of Cytomegalovirus…                                             Mamuye  Y.G  et al 





This is the first study to examine the rates of CMV 
infection among pregnant women in Ethiopia. The 
overall incidence rate of CMV IgG among 
pregnant women in our study was 88.5%, which is 
similar with other studies in different African 
countries: 97.5% in Sudan (14), 96% in Egypt 
(15), 92% in Nigeria (16) and 87% in Gambia 
(17). However, the results of this study were 
higher than those reported in developed countries. 
A relatively low sero-prevalence, 40%-60%, is 
reported, 46.8% from France (18), 56.3% in 
Finland (19) nd 60% in the United States (20). It 
seems that the prevalence of CMV infection 
observed in this study was similar to that reported 
in other developing communities but higher than 
in the developed one. This may be attributed to the 
low socioeconomic status and poor hygienic 
practices which might play significant roles in 
increasing rate of CMV infection.  
In the present study, the sero-prevalence of 
CMV IgM was 15.5% among the pregnant 
women, which reflected an active recent infection 
and reactivation of the virus. This finding was 4-7 
times higher than those in other different 
developing countries; 4% in Nigeria (16), 6% in 
Sudan (14), 2.5% in Iran (21),  1.7% in Korea (22) 
and/or even developed world studies from 
Belgium, Brazil, Taiwan, Cuba and Finland (23-
27). This might be due to low socio-economic 
status, the number of toddlers and poor hygienic 
practice. Poor hygienic practice, in particular, is a 
key source for the prevalent of infection. 
However, a similar rate of active infection has 
been reported from Poland (28), 15.9% in 
Kashmir valley (29) and India (30). Luckily, one 
woman (0.5%) out of the 31 IgM-positive 
Ethiopian women tested was IgG negative, 
indicating probably of a recent primary infection.  
In the current study, there was no 
independent factor which will increase the 
infection rates of cytomegalovirus among 
pregnant women (P≥ 0.05). These results suggest 
that all maternal age groups have equal chance of 
being infected by CMV infection. The current 
finding is in agreement with other studies (14,16).  
However, our finding is in contrast with other 
studies, illiterate women and women with high 
parity were at higher risk for CMV infection 
(21,31-33). This might be due to the differences in 
socio-demographic characteristics, various 
cultures and behaviors among these settings might 
have influence and determine epidemiology of 
CMV. In another study, it was found that low 
socioeconomic status is a strong risk factor for 
acquisition CMV infection (32).  
In the current study, 22(11.0%) of the 
participants were observed to be susceptible to 
primary CMV infection during their pregnancy. 
These women are at risk for congenital infection 
resulting from a primary infection due to maternal 
primary CMV infection, which leads to fetal 
infection in approximately 40% of cases (34). 
Since the incidence rate of primary infection 
among pregnant women is high, they are a critical 
group because the risk of congenital 
infection/following/after/resulting from a primary 
infection is much higher during primary infection 
in the pregnant women (2,34). Therefore, it would 
be beneficial to properly inform this category of 
women about the need for further investigations to 
detect prenatal infection and planning of 
appropriate intervention such as use of 
hyperimmune globulin or consented termination 
of pregnancy as an option.  
In many developing countries, the burden of 
CRS is under-estimated (35). Also, Ethiopia lacks 
information regarding the burden of CRS. In this 
study, Rubella specific IgM was 2.0% from 
pregnant women. This is in comparabel with other 
study; 2% in Sudan (36). Many cases of rubella 
are identified every year in Ethiopia by the 
measles surveillance system. However, there is 
currently no effective intervention for rubella in 
the country. Thus, an intensive type of research is 
important for the decision to introduce rubella-
containing vaccine in the national immunization 
program. 
Possible preventive measures including 
improved hygiene behavior of sero-negative 
pregnant women should be emplaced and routine 
maternal screening for primary infection using 
IgG avidity has to be made. Once diagnosed with 
the cytomegalovirus infection, treatment with 
hyperimmune globulin and safe administration of 
oral ganciclovir to mothers of CMV-infected 
fetuses, with no teratogenic side effects when 
given in the early stages of pregnancy should be 
supported (37,38). 
This study brought a new epidemiology of 
etiological agent in Ethiopia. It showed the high 
prevalence of cytomegalovirus infection in the 
setting. The study also showed the high prevalence 





of primary (recent and/or re-activation) infection 
and indicated the high risk of feta anomalies. 
Since this is the first study in the setting, the 
significance of information that contained in the 
study is not undermined by clinicians, researchers 
and policy makers.  
The following limitations should be taken 
into consideration. These include failure to use 
CMV IgG avidity test, which helps to identify 
between primary infection and reactivation. We 
were unable to address all the potential risk factors 
to CMV positivity like HIV/ADIS sero-status and 
income of the participants.  
In general, this study showed that there is a 
high sero-prevalence rate of CMV infection 
among pregnant women at our center. It is also 
likely to be a reflection of the overall high 
prevalence among adult Ethiopians. In addition to 
detecting high prevalence of CMV, detecting 
recent infection of rubella worsens the outcome of 
the disease. This finding therefore helps to create 
awareness among clinicians in Ethiopia, that rapid 
and accurate diagnosis of CMV infection in 
pregnant women is critical to prevent major 
associated complications. Future studies, including 
large scale surveillance throughout Ethiopia, are 
needed before national screening and universal 
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